ZIOPHARM Oncology Inc. (ZIOP)

5.41
0.28 5.50
NASDAQ : Health Technology
Prev Close 5.13
Open 5.10
Day Low/High 4.83 / 5.70
52 Wk Low/High 1.56 / 7.25
Volume 5.16M
Avg Volume 1.97M
Exchange NASDAQ
Shares Outstanding 162.55M
Market Cap 820.89M
EPS -0.50
P/E Ratio 4.76
Div & Yield N.A. (N.A)

Latest News

Ziopharm Oncology Announces Publication Of Positive Results Of Phase 1 Monotherapy Trial Of Controlled IL-12 In Patients With Recurrent Glioblastoma In Science Translational Medicine

Ziopharm Oncology Announces Publication Of Positive Results Of Phase 1 Monotherapy Trial Of Controlled IL-12 In Patients With Recurrent Glioblastoma In Science Translational Medicine

- Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma - - Median overall survival for Controlled IL-12 in patients receiving low-dose...

Ziopharm Oncology Reports Second Quarter 2019 Financial Results

Ziopharm Oncology Reports Second Quarter 2019 Financial Results

- FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for  patients with solid tumors at the National Cancer Institute (NCI) - - Exclusive license from NCI for library of T-cell receptors (TCRs) targeting neoantigens in the hotspots...

Ziopharm Oncology To Host Conference Call To Discuss Second Quarter 2019 Results On August 8, 2019

Ziopharm Oncology To Host Conference Call To Discuss Second Quarter 2019 Results On August 8, 2019

BOSTON, July 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8, at 8:30 a.

Ziopharm Oncology Announces $45 Million Warrant Exercise By Existing Shareholders In A Private Placement

Ziopharm Oncology Announces $45 Million Warrant Exercise By Existing Shareholders In A Private Placement

Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration

ZIOPHARM Oncology Reaches Analyst Target Price

ZIOPHARM Oncology Reaches Analyst Target Price

In recent trading, shares of ZIOPHARM Oncology Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $6.19/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ziopharm Oncology Names Sath Shukla As Chief Financial Officer

Ziopharm Oncology Names Sath Shukla As Chief Financial Officer

Joins from Vertex Pharmaceuticals; Served as global Head of Corporate Finance

Powell Apparently Looking for Reasons to Give the Market the Rate Cuts It Wants

Powell Apparently Looking for Reasons to Give the Market the Rate Cuts It Wants

Now the focus is on how many more cuts will follow.

Ziopharm Oncology Names NCI's Dr. Drew Deniger To Direct TCR-T Cell Therapy Program

Ziopharm Oncology Names NCI's Dr. Drew Deniger To Direct TCR-T Cell Therapy Program

- Dr. Deniger joins from National Cancer Institute to lead Ziopharm's non-viral T-cell program targeting neoantigens for personalized immunotherapy of solid tumors -

Interesting ZIOP Put And Call Options For August 16th

Interesting ZIOP Put And Call Options For August 16th

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

March 2021 Options Now Available For ZIOPHARM Oncology (ZIOP)

March 2021 Options Now Available For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available today, for the March 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 637 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ZIOPHARM Oncology Reaches Analyst Target Price

ZIOPHARM Oncology Reaches Analyst Target Price

In recent trading, shares of ZIOPHARM Oncology Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $6.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Interesting ZIOP Put And Call Options For March 15th

Interesting ZIOP Put And Call Options For March 15th

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new March 15th contracts and identified one put and one call contract of particular interest.

First Week Of ZIOP February 15th Options Trading

First Week Of ZIOP February 15th Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

First Week Of ZIOP July 2019 Options Trading

First Week Of ZIOP July 2019 Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the July 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of ZIOP November 16th Options Trading

First Week Of ZIOP November 16th Options Trading

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

Interesting ZIOP Put And Call Options For January 2021

Interesting ZIOP Put And Call Options For January 2021

Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting ZIOP Put And Call Options For April 2019

Interesting ZIOP Put And Call Options For April 2019

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the April 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of ZIOP September 21st Options Trading

First Week Of ZIOP September 21st Options Trading

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

ZIOPHARM Oncology Breaks Above 200-Day Moving Average - Bullish For ZIOP

In trading on Wednesday, shares of ZIOPHARM Oncology Inc crossed above their 200 day moving average of $4.72, changing hands as high as $4.88 per share. ZIOPHARM Oncology Inc shares are currently trading up about 9.7% on the day.

First Week Of June 15th Options Trading For ZIOPHARM Oncology (ZIOP)

Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

Ziopharm Oncology Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Corporate Update

Ziopharm Oncology Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Corporate Update

Company to host conference call today at 4:30 p.m. ET

Short Interest Increases 13.4% For ZIOP

Short Interest Increases 13.4% For ZIOP

The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 4,176,071 share increase in total short interest for ZIOPHARM Oncology Inc , to 35,317,685, an increase of 13.41% since 01/31/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ziopharm Oncology Presents Data On Very Rapid Production Of CAR T Cells At Keystone Symposia Emerging Cellular Therapies: T Cells And Beyond

Ziopharm Oncology Presents Data On Very Rapid Production Of CAR T Cells At Keystone Symposia Emerging Cellular Therapies: T Cells And Beyond

Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies

ZIOP: Insiders vs. Shorts

ZIOP: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/12/2018 settlement date, and ZIOPHARM Oncology Inc is one of the most shorted stocks of the Russell 3000, based on 17.77 "days to cover" versus the median component at 4.53. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.